Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Lymphocyte Predominant Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Conditions
Brief summary
This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did not respond to previous therapy. Bortezomib is an inhibitor of protein degradation. Bortezomib degrades short-lived regulatory proteins in the cell, and has been reported to increase the tumor cells. Bortezomib may increase the effectiveness of ifosfamide and vinorelbine (two standard drugs given to children with Hodgkin Lymphoma that has come back after initial treatment) by making cancer cells more sensitive to effectiveness of standard chemotherapy by preventing anti-death responses in these drugs. Giving bortezomib together with ifosfamide and vinorelbine tartrate should kill more cancer cells than are killed with ifosfamide and vinorelbine alone.
Detailed description
PRIMARY OBJECTIVES: I. Determine the efficacy and safety of bortezomib (as a chemosensitizing agent) in pediatric patients and young adults with primary refractory Hodgkin's lymphoma (HL) or HL in first relapse. II. Determine the response rate in patients treated with bortezomib, ifosfamide, and vinorelbine ditartrate (vinorelbine tartrate) (IVB) and compare the response rate to the historical response rate in patients treated with ifosfamide and vinorelbine ditartrate alone. SECONDARY OBJECTIVES: I. Determine the overall response rate (complete and partial response) and induction success rate after 2 or 4 courses of therapy and the reinduction rate (complete response) after 4 courses of therapy. II. Determine the proportion of patients able to mobilize sufficient hematopoietic stem cells (CD34+) after 2 courses of IVB. OUTLINE: This is a multicenter, open-label, pilot study. Patients receive ifosfamide intravenously (IV) continuously over days 1-4, vinorelbine tartrate IV over 6-10 minutes on days 1 and 5, and bortezomib intravenously on days 1, 4, and 8, and filgrastim (G-CSF) by vein or subcutaneously beginning on day 6 and continuing until blood counts recover or peripheral blood stem cells (PBSC) are harvested. Treatment cycles repeat every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy. After completion of study treatment, patients are followed every 6 months for 2 years and then annually thereafter.
Interventions
Given IV
Given IV
Given IV
Given IV or SC
Sponsors
Study design
Eligibility
Inclusion criteria
* Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria: * Stage I-IV disease * No morphologically unclassifiable disease * Meets 1 of the following criteria: * Mixed cellularity * Lymphocytic depletion (LD) * LD, diffuse fibrosis * LD, reticular * Lymphocyte predominance (LP) * LP, diffuse * LP, nodular * Nodular sclerosis (NS) * NS, cellular phase * NS, lymphocytic predominance * NS, mixed cellularity * NS, LD * Not otherwise specified * Primary refractory disease OR disease in first relapse, except for the following: * Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy * Patients on the observation-only arm of protocol COG-AHOD0431 * Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney) * Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met: * Platelet count ≥ 20,000/mm³ (platelet transfusion allowed) * Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed) * Karnofsky performance status (PS) 60-100% (for patients \> 16 years of age) OR Lanksy PS 60-100% (for patients =\< 16 years of age) * Life expectancy \>= 2 months * Absolute neutrophil count \>= 1,000/mm\^3 * Platelet count \>= 75,000/mm\^3 (transfusion independent) (for patients with no bone marrow involvement) * Creatinine =\< 1.5 times upper limit of normal (ULN) * Creatinine clearance or radioisotope glomerular filtration rate \>= 70 mL/min/1.73 m\^2 * AST and ALT =\< 2.5 times ULN * Bilirubin =\< 1.5 times ULN * Shortening fraction \>= 27% by echocardiogram OR LVEF \>= 50% by gated radionuclide study * Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled * No CNS toxicity \> grade 2 * No serious intercurrent illnesses * No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs * No peripheral neuropathy \> grade 1 * No known hypersensitivity to bortezomib, boron, or mannitol * No other concurrent chemotherapy or immunomodulating agents (including steroids) * Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions * No dexamethasone or aprepitant as an antiemetic * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Recovered from prior therapy * No prior bortezomib or other proteasome inhibitors * At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas) * More than 14 days since prior investigational drugs * No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants * Benzodiazepine or gabapentin allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) | After 2 cycles of treatment | CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Grade 3 or 4 Toxicity | 4 weeks following completion of therapy | Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy |
| Overall Response Rate | After 2 cycles and 4 cycles | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Induction Success Rate | After 2 cycles and 4 cycles | Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to \< grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of \>2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.) |
| Rate of Successful PBSC Harvest | After 2 cycles | Success is defined as the ability to harvest 2x10\^6 CD34+ cells/kg within 5 collection days. |
| Biological Markers | Before, during, and after treatment | Assessing baseline NF-kB protein levels in tumor tissue |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.
ifosfamide: Given IV
bortezomib: Given IV
vinorelbine ditartrate: Given IV
filgrastim: Given IV or SC | 26 |
| Total | 26 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Ineligible | 1 |
| Overall Study | Lack of Efficacy | 3 |
| Overall Study | Protocol Violation | 1 |
Baseline characteristics
| Characteristic | Treatment (Ifosfamide, Vinorelbine, Bortezomib) |
|---|---|
| Age, Categorical <=18 years | 23 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Age, Continuous | 15.9 years STANDARD_DEVIATION 2.6 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 22 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 18 Participants |
| Region of Enrollment Australia | 1 participants |
| Region of Enrollment Canada | 2 participants |
| Region of Enrollment United States | 23 participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 18 / 25 |
| serious Total, serious adverse events | 4 / 25 |
Outcome results
Complete Response (CR)
CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging.
Time frame: After 2 cycles of treatment
Population: Analysis population includes all patients evaluable for tumor response. Three enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Complete Response (CR) | With CR | 2 participants |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Complete Response (CR) | Without CR | 21 participants |
Biological Markers
Assessing baseline NF-kB protein levels in tumor tissue
Time frame: Before, during, and after treatment
Population: Corresponding data were not collected
Induction Success Rate
Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to \< grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of \>2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.)
Time frame: After 2 cycles and 4 cycles
Population: There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Induction Success Rate | Induction Success Rate (After 2 cycles) | 19 Participants |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Induction Success Rate | Induction Success Rate (After 4 cycles) | 12 Participants |
Number of Participants With Grade 3 or 4 Toxicity
Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy
Time frame: 4 weeks following completion of therapy
Population: 25 patients reported, 1 ineligible patient not included in adverse events.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Number of Participants With Grade 3 or 4 Toxicity | 9 Participants |
Overall Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: After 2 cycles and 4 cycles
Population: There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Overall Response Rate | Overall Response Rate (After 2 cycles) | 19 Participants |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Overall Response Rate | Overall Response Rate (After 4 cycles) | 12 Participants |
Rate of Successful PBSC Harvest
Success is defined as the ability to harvest 2x10\^6 CD34+ cells/kg within 5 collection days.
Time frame: After 2 cycles
Population: Analysis population includes all patients evaluable after cycle 2. Six enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error, 3 who did not have recorded data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | Rate of Successful PBSC Harvest | 19 Participants |